POSB16 Overall Survival Indirect Treatment Comparison Results Adjusted for Treatment Crossover: Brigatinib Relative to Alectinib in Patients with ALK+ NSCLC Previously Untreated with an ALK Inhibitor Using the Final Results from Alta-1L and Alex. - Cranmer, H; Lin, HM; Kay, S; Cazzato, S (Value in Health, 2022)